Last $37.77 USD
Change Today -0.20 / -0.53%
Volume 131.5K
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:34 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

isease diagnosis, methods for determining disease progression, methods for correlation claims, and methods for disease treatment, and general molecular diagnostic techniques. The following is a summary of U.S. patents covering its molecular diagnostic tests and companion diagnostic services. Many of the issued U.S. patents relating to BRACAnalysis, COLARIS, COLARIS AP, MELARIS, PREZEON, PANEXIA and TruCulture also have related foreign issued patents in various countries, including in Europe, Canada, Japan, Australia and New Zealand, claiming similar subject matter and having similar expiration dates. BRACAnalysis: The company owns or has exclusive license rights to approximately 500 claims in 24 issued U.S. patents relating to BRACAnalysis testing. These patents contain multiple claims, including claims relating to compositions of matter on synthetic BRCA1 and BRCA2 nucleic acids, probes and primers, methods of detecting genetic mutations in the BRCA1 and BRCA2 genes and the use thereof for diagnosing predisposition to breast or ovarian cancer, and general molecular diagnostic technology relating to BRACAnalysis testing. BART: The company owns or has exclusive license rights to seven issued U.S. patents relating to BART testing. These U.S. patents have terms that are expected to expire commencing in 2015, with the last patent expected to expire in 2025. These patents contain multiple claims, including but not limited to claims relating to composition of matter on synthetic BRAC1 and BRCA2 nucleic acids, composition of matter on probes and primers, methods of detecting genomic rearrangements and methods of determining BRCA1 and BRCA2 related predisposition to cancer. COLARIS: The company owns or has exclusive or non-exclusive license rights to 19 issued U.S. patents relating to COLARIS testing. These U.S. patents have terms that are expected to expire commencing in 2013, with the last patent expected to expire in 2023. These patents contain multiple claims, including but not limited to claims relating to MLH1, MSH2, PMS2 and MYH compositions of matter on synthetic MLH1, MSH2, PMS2 and MYH nucleic acids, methods of detecting mutations in the MLH1, MSH2 and MYH genes, methods for determining MLH1-, MSH2-, PMS2-, and MYH- related predisposition to cancer, such as Lynch Syndrome cancers, and general molecular diagnostic technology applicable to COLARIS testing. COLARIS AP: The company owns or has exclusive license rights to 11 issued U.S. patents relating to COLARIS AP testing. These U.S. patents have terms that are expected to expire commencing in 2017, with the last patent expected to expire in 2026. MELARIS: The company owns or has exclusive license rights to five issued U.S. patents relating to MELARIS testing. These patents contain multiple claims, including claims relating to methods of detecting mutations in the p16 gene and their use for diagnosing predisposition to melanoma, and general molecular diagnostic technology applicable to MELARIS testing. PANEXIA: The company owns or has exclusive license rights to eight U.S. patents and two U.S. patent applications relating to PANEXIA testing. PREZEON: The company has exclusive license rights to six issued U.S. patents relating to PREZEON testing. These patents contain multiple claims, including but not limited to claims relating to PTEN compositions of matter on antibodies, methods of detecting PTEN expression and PTEN mutations, and methods of detecting cancer or a predisposition to cancer using PTEN, and methods of guiding therapeutic treatment decisions based on PTEN status. Prolaris: The company owns or has exclusive license rights to six U.S. patent applications relating to Prolaris testing. TheraGuide 5-FU: The company owns one U.S. patent and one U.S. patent application relating to TheraGuide 5-FU testing. The patent would expire in 2023. TruCulture: The company has exclusive license rights to commercialize technology covered by one issued U.S. patent for its TruCulture product. This patent contains multiple claims, including but not limited to claims relating to methods and kits for determining the immune defense activity of blood.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $37.81 USD -0.16

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Labs Inc $30.75 USD +0.51
Foundation Medicine Inc $27.21 USD +0.45
Genomic Health Inc $27.49 USD +0.30
Imperial Innovations Group PLC 460.00 GBp +8.50
NeoGenomics Inc $5.23 USD -0.015
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 16.2x
Price/Sales 3.7x
Price/Book 3.9x
Price/Cash Flow 15.2x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.